New York, USA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 30+ Companies Working in the Domain
The prevalence of Psoriatic Arthritis has been rising since the past few years, which prompts the growing demand for the treatment options. The market is driven by the increasing prevalence of chronic or long-term skin diseases, including psoriasis, and the rapidly growing geriatric population. The Companies developing the potential therapies in the last stage of development include Sun Pharmaceutical Industries, Bio-Thera Solutions, ACELYRIN Inc., and several others.
DelveInsight’s 'Psoriatic Arthritis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline psoriatic arthritis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the psoriatic arthritis pipeline domain.
Key Takeaways from the Psoriatic Arthritis Pipeline Report
- DelveInsight’s psoriatic arthritis pipeline report depicts a robust space with 30+ active players working to develop 33+ pipeline therapies for psoriatic arthritis treatment.
- Key psoriatic arthritis companies such as Sun Pharmaceutical Industries Limited, UCB Biopharma, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Polpharma Biologics, Avotres, XBiotech, Aclaris Therapeutics, Luye Pharma Group, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nimbus Therapeutics, f5 Therapeutics, MoonLake Immunotherapeutics, and others are evaluating new drugs for psoriatic arthritis to improve the treatment landscape.
- Promising psoriatic arthritis pipeline therapies in various stages of development include Tildrakizumab, Bimekizumab, BMS-986165, AbGn-168H, Izokibep, BAT2506, Ustekinumab biosimilar, Apremilast, QX 002N, KPG-612, ALPN 101, AVT001, RHE 70202, ATI-450, Secukinumab biosimilar, DNX 114, SHR 1314, NDI-034858, Research programme: Autoimmune disorder therapeutics, Sonelokimab, and others.
- In November 2022, Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase III Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis.Data from BE OPTIMAL showed that clinical joint and skin clearance responses in patients with active psoriatic arthritis were sustained to week 52 with bimekizumab treatment.In addition, data from BE MOBILE 1 and BE MOBILE 2 showed that across the full spectrum of axSpA, encompassing nr-axSpA and AS, treatment with bimekizumab resulted in sustained improvement in the signs and symptoms of disease, including suppression of inflammation and improvements in physical function and quality of life, to week 52.
- In November 2022, ACELYRIN, INC., announced additional data from a Phase II trial of izokibep in psoriatic arthritis (PsA) to be presented at the American College of Rheumatology (ACR) Convergence 2022. Izokibep showed consistently high levels of response across multiple disease measures of joint and skin improvement, beginning early and with ongoing improvement. The safety profile of izokibep was generally consistent with other IL-17A inhibitors, and in the trial, event rates were mostly similar to placebo.
- In August 2022, The Food and Drug Administration (FDA) expanded the approval of Stelara® (ustekinumab) to include treatment of pediatric patients 6 years of age and older with active psoriatic arthritis (PsA). The approval was supported by evidence from adequate and well-controlled studies of Stelara in adults with psoriasis and PsA, pharmacokinetic (PK) data from adult patients with psoriasis, adult patients with PsA and pediatric patients with psoriasis, and safety data from 2 clinical studies in 44 patients 6 to 11 years old with psoriasis and 110 patients 12 to 17 years old with psoriasis.
- In May 2022, ACELYRIN, INC., Affibody AB, and Inmagene Biopharmaceuticals Co., Ltd. announced that a 16-week, global, Phase II clinical trial of izokibep in 135 patients with psoriatic arthritis (PsA) met its primary endpoint of ACR50. Izokibep also achieved secondary endpoints, including PASI response, enthesitis LEEDs improvement, and quality of life improvement on a clinically validated PsA-specific quality of life instrument, the Psoriatic Impact of Disease (PsAID) questionnaire.
- In January 2022, AbbVie announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.The FDA approval was supported by data from two pivotal studies, KEEPsAKE-1 and KEEPsAKE-2, which evaluated the efficacy and safety of SKYRIZI in adults with active PsA, including those who had responded inadequately or were intolerant to biologic therapy and non-biologic disease-modifying antirheumatic drugs (DMARDs).
Request a sample and discover the recent advances in psoriatic arthritis treatment drugs @Psoriatic Arthritis Pipeline Report
The psoriatic arthritis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage psoriatic arthritis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the psoriatic arthritis clinical trial landscape.
Psoriatic Arthritis Overview
Psoriatic Arthritis is a chronic inflammatory joint disease that is often associated with psoriasis. It can cause pain, stiffness, swelling, and joint destruction in both peripheral joints and the axial skeleton. This joint pathology develops slowly and is more annoying than disabling. Seronegative spondyloarthropathies include psoriatic arthritis.
Besides, psoriatic arthritis causes and pathogenesis are not completely understood as it involves a complex interaction between genetic and environmental factors resulting in immune-mediated inflammation involving the skin and joints and may involve other organs.
Psoriatic arthritis symptoms are frequently similar to those of rheumatoid arthritis. Both diseases cause painful, swollen, and warm-to-the-touch joints. As there is no specific test for psoriatic arthritis, your doctor will make a psoriatic arthritis diagnosis based on the symptoms and a physical examination.
Find out more about psoriatic arthritis treatment drugs @Drugs for Psoriatic Arthritis Treatment
A snapshot of the Psoriatic Arthritis Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Tildrakizumab | Almirall/Sun Pharmaceutical Industries | Pre-registration | Antibody-dependent cell cytotoxicity; Interleukin-23 subunit p19 inhibitors; T lymphocyte stimulants | Subcutaneous |
| BAT2506 | Bio-Thera Solutions | Phase III | Tumour necrosis factor alpha inhibitors | Subcutaneous |
| ABY-035 | ACELYRIN Inc. | Phase II | IL17A protein inhibitors | Subcutaneous |
| QX 002N | Qyuns Therapeutics | Phase I | Interleukin-17 inhibitors | Injectable |
| Acazicolcept | Alpine Immune Sciences | Preclinical | CD28 antigen inhibitors; Inducible T-cell co-stimulator protein antagonists | NA |
| KPG-612 | Kangpu Biopharmaceuticals | Preclinical | Type 4 cyclic nucleotide phosphodiesterase inhibitors | NA |
| RHE 70202 | XBiotech27 | Preclinical | Interleukin 1 alpha inhibitors | NA |
Learn more about the emerging psoriatic arthritis pipeline therapies @Psoriatic Arthritis Clinical Trials
Psoriatic Arthritis Therapeutics Assessment
The psoriatic arthritis pipeline report proffers an integral view of psoriatic arthritis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Psoriatic Arthritis Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Interleukin-23 subunit p19 inhibitors, T lymphocyte stimulants, Interleukin-17 inhibitors, Type 4 cyclic nucleotide phosphodiesterase inhibitors, CD28 antigen inhibitors, Inducible T-cell co-stimulator protein antagonists, Interleukin 1 alpha inhibitors
- Key Psoriatic Arthritis Companies: Sun Pharmaceutical Industries Limited, UCB Biopharma, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Polpharma Biologics, Avotres, XBiotech, Aclaris Therapeutics, Luye Pharma Group, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Nimbus Therapeutics, f5 Therapeutics, MoonLake Immunotherapeutics, and others.
- Key Psoriatic Arthritis Pipeline Therapies: Tildrakizumab, Bimekizumab, BMS-986165, AbGn-168H, Izokibep, BAT2506, Ustekinumab biosimilar, Apremilast, QX 002N, KPG-612, ALPN 101, AVT001, RHE 70202, ATI-450, Secukinumab biosimilar, DNX 114, SHR 1314, NDI-034858, Research programme: Autoimmune disorder therapeutics, Sonelokimab, and others.
Dive deep into rich insights for new drugs for psoriatic arthritis treatment; visit @Psoriatic Arthritis Drugs
Table of Contents
| 1. | Psoriatic Arthritis Pipeline Report Introduction |
| 2. | Psoriatic Arthritis Pipeline Report Executive Summary |
| 3. | Psoriatic Arthritis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Psoriatic Arthritis Clinical Trial Therapeutics |
| 6. | Psoriatic Arthritis Pipeline: Late Stage Products (Pre-registration) |
| 6.1 | Tildrakizumab: Almirall/Sun Pharmaceutical Industries |
| 7. | Psoriatic Arthritis Pipeline: Late Stage Products (Phase III) |
| 7.1 | BAT2506: Bio-Thera Solutions |
| 8. | Psoriatic Arthritis Pipeline: Mid Stage Products (Phase II) |
| 8.1 | ABY-035: ACELYRIN Inc. |
| 9. | Psoriatic Arthritis Pipeline: Early Stage Products (Phase I) |
| 9.1 | QX 002N: Qyuns Therapeutics |
| 10. | Psoriatic Arthritis Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Psoriatic Arthritis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Psoriatic Arthritis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the psoriatic arthritis pipeline therapeutics, reach out @Psoriatic Arthritis Medications
Related Reports
Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriatic arthritis companies including UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, among others.
Psoriatic Arthritis Epidemiology Forecast
Psoriatic Arthritis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted psoriatic arthritis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Psoriasis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key psoriasis companies, including Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, among others.
Psoriasis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key psoriasis companies, including Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus BioSciences, among others.
Psoriasis Epidemiology Forecast
Psoriasis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
For more insights, browse through our latest blog on Psoriatic Arthritis Treatment Market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
